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ABSTRACT
Melanoma remains one of the most aggressive and therapy-resistant cancers. 
Finding new treatments to improve patient outcomes is an ongoing effort. We 
previously demonstrated that melanoma relies on the activation of ERBB signaling, 
specifically of the ERBB3/ERBB2 cascade. Here we show that melanoma tumor 
growth is inhibited by 60% over controls when treated with lapatinib, a clinically 
approved inhibitor of ERBB2/EGFR. Importantly, tumor growth is further inhibited 
to 85% when the natural compound fucoidan from New Zealand U. pinnatifida is 
integrated into the treatment regimen. Fucoidan not only enhances tumor growth 
inhibition, it counteracts the morbidity associated with prolonged lapatinib treatment. 
Fucoidan doubles the cell killing capacity of lapatinib. These effects are associated 
with a further decrease in AKT and NFκB signaling, two key pathways involved in 
melanoma cell survival. Importantly, the enhancing cell killing effects of fucoidan can 
be recapitulated by inhibiting ERBB3 by either a specific shRNA or a novel, selective 
ERBB3 neutralizing antibody, reiterating the key roles played by this receptor in 
melanoma. We therefore propose the use of lapatinib or specific ERBB inhibitors, 
in combination with fucoidan as a new treatment of melanoma that potentiates the 
effects of the inhibitors while protecting from their potential side effects.
INTRODUCTION
Although newly available therapies have improved 
the life expectancy of melanoma patients, they still 
come short at stopping the disease. Melanomas are 
very aggressive cancers that rely on the activity of 
multiple signaling pathways for their growth, survival 
and propagation, and adapt quickly to new treatments 
becoming resistant. Novel therapeutic interventions are 
needed to acquire better long-lasting effects.
We have recently shown that melanomas express 
high levels of ERBB3 and depend on its function for 
growth and survival [1, 2]. Specifically, we have shown 
that ERBB3 is highly active (phosphorylated) in up 
to 70% of melanomas regardless of whether they carry 
mutated or wild type BRAF, the most common oncogenic 
driver in melanoma [3]. ERBB3 is one of four members 
of the ERBB family of tyrosine kinase receptors that are 
often inappropriately reactivated in various cancers. All 
ERBB receptors function by dimerizing with members of 
the family to trigger growth/survival signals. ERBB3 is 
the only member of the ERBB family that lacks tyrosine 
kinase activity, and as such, requires dimerization with 
other tyrosine kinase receptors to trigger a signaling 
pathway. While ERBB3 can potentially dimerize with all 
members of the ERBB family, several lines of evidence 
show that the strongest dimer to activate survival pathways 
like AKT in breast cancer is the ERBB3/ERBB2 dimer 
[4–7]. Similarly, in melanoma, we have demonstrated that 
ERBB3/ERBB2 is a key survival signaling unit that acts 
mostly by activating AKT [2]. Additionally, ERBB3 up-
regulation is also a mechanism of resistance to anti-BRAF 
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therapies [8]; and has been shown to promote melanoma 
metastasis [9].
Lapatinib is a small molecule tyrosine kinase 
inhibitor with a similar IC50 against ERBB2 and EGFR. 
Lapatinib is approved by the FDA for the treatment of 
ERBB2 positive breast cancer patients. We have shown 
that lapatinib inhibits ERBB3 signaling and hampers 
melanoma cell survival and tumorigenesis [3]. In 
particular, lapatinb works better when combined with 
other inhibitors of key pathways in melanoma, such 
as γ-secretase inhibitors [3], and BRAF inhibitors [8], 
highlighting a cooperation among different pathways 
in melanoma pathogenesis. Additionally, although 
generally considered well tolerated, lapatinib can lead to 
gastrointestinal side effects such as diarrhea, nausea and 
vomiting that can result in some weight loss, skin rash and 
fatigue [10]. Hence, means to potentiate its effectiveness 
while improving its tolerability would be highly desirable.
Natural compounds and supplements have become 
part of people’s daily life. Of note, over 70% of anti-
cancer agents have their origin in natural sources [11]. In 
particular, marine derived products have sparked a great 
interest in recent years given the vast natural resource [11].
Fucoidan is a highly sulfated polysaccharide of 
brown algae with anti-inflammatory, anticoagulant, anti-
tumor and anti-angiogenic activities [12–17]. Fucoidan 
extracted from Undaria pinnatifida has shown anti-
cancer activity against mouse and human cancer cell lines 
[18–20]. Fucoidan extracted from the New Zealand U. 
pinatifida employed here, has been reported to possess 
better anti-cancer activity at relatively lower doses with 
respect to pure fucoidan [20]. The safety of fucoidan is 
demonstrated by a number of animal studies [21] and by 
the fact that fucoidan-containing food supplements or 
drinks have been traditionally given to cancer patients in 
several countries [22]. Also, recent studies have shown 
fucoidan can synergize with standard anti-cancer agents 
and/or can reduce their toxicity [23].
Here we demonstrate that fucoidan extracted from 
the New Zealand seaweed U. pinnatifida synergizes with 
lapatinib by doubling its cell killing capacity towards 
several melanoma cell lines. These effects are associated 
with a further reduction of AKT and NFκB activity. 
Specific inhibition of ERBB3 by either shRNA or a 
novel neutralizing antibody [24–26] in combination with 
fucoidan partly recapitulated these effects, reiterating 
the ERBB3 pathway is a major player in melanoma cell 
survival. Finally, we found that fucoidan, while enhancing 
the anti-cancer effects of lapatinib, improves the animal 
welfare, rescuing weight loss that often accompanies 
lapatinib-based therapies. Taken together, these results 
indicate a combination therapy involving the clinical drug 
lapatinib or ERBB3 inhibitors, and the natural compound 
fucoidan may be a novel, safer treatment option for 
melanoma patients characterized by increased ERBB 
activity.
RESULTS
Fucoidan extracted from New Zealand 
U. pinnatifida enhances the therapeutic effects of 
lapatinib
We have recently shown that up to 70% of 
melanomas, regardless of whether they possess mutated or 
wild type BRAF, show hyper-activation of ERBB3 [3] and 
rely on an ERBB3/ERBB2 signaling cascade to promote 
cell survival [2]. Indeed, lapatinib, a clinical ERBB2 
and EGFR inhibitor, effectively inhibited the ERBB3/
ERBB2 pathway and importantly, delayed melanoma 
tumor growth in both mutated and wild type BRAF cells 
[3]. Although effective, lapatinib only slowed down tumor 
growth. Hence, we sought to improve the anti-tumor 
activity of lapatinib while keeping its concentration within 
safe therapeutic doses.
The ability of fucoidan to synergize with standard 
anti-cancer agents and/or reduce toxicity has recently 
been investigated (reviewed in [23]). We therefore tested 
the effects of fucoidan on WM266-4 melanoma cells and 
found that while fucoidan alone at different concentrations 
did not affect cell viability, measured as the total ATP 
content in cells (Cell Titer Glo Assay), it synergized with 
lapatinib, with the highest combinatorial effect at 1mg/ml 
fucoidan (Figure 1A, 1B). To determine if the synergistic 
inhibition of viability affected a variety of melanoma 
subtypes, cells with different genetic drivers were 
subjected to a three-day treatment with 10μM lapatinib and 
1mg/ml fucoidan. Independent of the genetic background, 
addition of fucoidan further decreased cell viability over 
lapatinib alone (Figure 1C). Fucoidan doubled the killing 
activity of lapatinib, bringing the percentage of cell death 
form 30-40% by lapatinib, to 70-80% for the combination 
(Figure 1D), after three days of treatment. At 24 hours we 
also observed doubling of cell death, although to a lower 
degree, likely given the shorter treatment time, measured 
as the percent of sub-G1 population by cell cycle analysis 
(Supplementary Figure S1). Importantly, although the 
viability of normal human fibroblasts (BJs) was decreased 
(Figure 1C) indicating either decreased mitochondrial 
output and/or decreased growth, the drugs did not induce 
cell death (Figure 1D), even after exposure to the drugs 
for up to six days (not shown). These data would indicate 
tumor specificity of the treatment with negligible toxicity 
to normal cells.
Fucoidan further decreases AKT and NFκB 
activity driven by lapatinib
The ability of fucoidan to interfere with a wide range 
of biological functions can in part be ascribed to its ability 
to interfere with several signaling pathways. For example, 
it has been shown to inhibit AKT [13], while it can either 
inhibit or promote ERK phosphorylation depending on 
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the cell types [27, 28]. Also, it can affect angiogenesis by 
decreasing VEGF signaling [29]; and can decrease EGF 
induced EGFR phosphorylation [30].
Akt and NFκB are major survival pathways 
that we have shown play a major role downstream of 
ERBB signaling in melanoma [3]. Hence, we wanted to 
determine whether treatment with fucoidan in combination 
with lapatinib would further enhance the inhibitory 
activity of the latter on AKT and NFκB. As previously 
shown, lapatinib inhibited both factors (Figure 2A, 2B), 
however, the addition of fucoidan further decreased the 
activity of AKT and NFκB after stimulation with the 
ERBB3 ligand neuregulin1 (NRG1). Similar results were 
obtained in another melanoma cell line (Supplementary 
Figure S2). This suggests fucoidan enhances the killing 
capacity of lapatinib in part by increasing the suppression 
of these survival cascades downstream of ERBB3. Indeed, 
expression of a constitutively active AKT or of the NFκB 
isoform p65 (Figure 3A), rescued almost to the levels 
of controls, viability and survival of cells treated with 
lapatinb alone or with the lapatinib/fucoidan combination 
(Figure 3B).
The inhibitory effects on AKT signaling may be 
ascribed to the fact that fucoidan further inhibits the 
activation of ERBB3 and ERBB2 (shown as reduced 
phosphorylation in Figure 2A). On the other hand, we 
did not observe any signal from EGFR, another target 
of lapatinib, in cells stimulated with NRG1. EGFR was 
however activated by its specific ligand EGF (Figure 2A). 
This observation is intriguing and supports our previous 
finding of a key role of an ERBB3/ERBB2 signaling unit 
in triggering AKT signaling and survival in melanoma 
cells [2]. Indeed, when cells were subjected to EGFR 
specific (gefitinib) or ERBB2 specific (TAK165) inhibitors 
in combination with fucoidan, a synergistic inhibition 
of cell viability was only observed in cells treated with 
the ERBB2 inhibitor (Supplementary Figure S3). These 
data suggest fucoidan amplifies the effects of drugs that 
specifically inhibit the ERBB3/ERBB2 signaling pathway 
in melanoma.
Figure 1: Fucoidan synergizes with lapatinib. A. Viability of WM266-4 cells at different doses of fucoidan alone or in combination 
with lapatinib. B. Combination indexes (CI) as a function of fraction affected (Fa) (CI<1: synergism; CI=1: additive; CI>1= antagonism). 
C. Viability of BRAFmut (WM115, WM266-4), RASmut (SKMel-2) and WT/WT (FEMX, MeWo) melanoma cells treated for three days with 
10μM lapatinib, 1mg/ml fucoidan, alone or combined. (+p<0.05); (*p<0.05); (@p<0.001; #p<0.05; ¶,§p<0.01. D. % cell death of two cell lines 
treated as in C (*,**p<0.0001). BJ fibroblasts were treated as the tumor cells. Results are the average of three independent experiments.
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Figure 2: The combination lapatinib-fucoidan enhances the inhibition of AKT and NFκB. Phospho-ERBB3, phospho-
ERBB2, phospho-EGFR, total and phospho-AKT A. and NFκB activity B. measured in WM266-4 pretreated O/N with lapatinib (10μM), 
fucoidan (1mg/ml) alone or combined and then stimulated with 10 ng/ml neuregulin1 (NRG1) for 10 minutes prior protein lysate collection. 
EGF (10ng/ml) was used as positive control for phospho-EGFR. Data are representative of four independent experiments. Densitometric 
analysis of the band intensity was done using ImageJ. Fold change of band intensity is the ratio between phospho-AKT and GAPDH. 
Significant decrease in phospho-AKT upon lapatinib and lapatinib/fucoidan treatment was observed with respect to NRG1 stimulated cells: 
*pLAP vs DMSO-NRG1=0.0004; **pL+F vs DMSO-NRG1=0.0003; 
#pL+F vs Lap<0.005, Student’st test.
Figure 3: Over-expression of activated AKT and p65-NFκB rescues cell viability and survival. A. expression of constitutive 
active Akt (left) and p65-NFκB (right) in WM266-4 cells. pLM: empty vector control. B. Viability (Cell titer glo-ATP) and survival (Trypan 
blue –TP) of the cells in A after three days in the presence of lapatinib (10uM) and fucoidan (1mg/ml) either alone or in combination. 
Significant differences in viability and survival, calculated by Student’s t test, was observed in both AKT and NFκB over-expressing cells 
and both in lapatinib and lapatinib/fucoidan treatments.
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Addition of fucoidan enhances the antitumor 
activity of lapatinib and improves animal 
wellbeing
Given the intriguing in vitro results, we wanted to 
test whether the combination of fucoidan with lapatinib 
would enhance the anti-tumor effects of lapatinib in vivo. 
Immunodeficient mice were inoculated intradermally 
with WM266-4 cells. When tumors in all mice reached 
an average size of 100-120mm3, the animals were 
divided into four groups of treatments: 1) DMSO (Ctrl); 
2) fucoidan (400mg/Kg s.c. [31]); Lapatinib (50mg/
Kg I.P. [32]); 4) fucoidan+lapatinib. Mice were treated 
five days a week for three weeks and weighed once a 
week to assess their general wellbeing. The data show 
that fucoidan affected tumor growth, though not in a 
significant manner, whereas lapatinib inhibited growth 
roughly by 60% with respect to controls. Addition 
of fucoidan further decreased tumor growth to 85% 
(Figure 4A, 4B). Importantly, while a 10% body 
weight loss was observed in lapatinib treated mice 
(Figure 4C), the addition of fucoidan ameliorated the 
overall animal welfare as indicated by the maintenance 
of weight and diminished liver toxicity due to lapatinib 
(Figure 4C, 4D). These results suggest a therapy 
combining the ERBB inhibitor lapatinib at clinical 
therapeutic doses with the natural compound fucoidan 
can enhance the therapeutic benefits of Lapatinib while 
decreasing its side effects.
ERBB3 inhibition recapitulates the effects of 
lapatinib
We have shown that lapatinib effectively inhibits 
the activation of ERBB3 [3]. We therefore wanted 
to determine whether specific ERBB3 inhibition 
could recapitulate the effects observed with lapatinb 
particularly when combined with fucoidan. We 
inhibited ERBB3 by either a specific shRNA (shB3) 
[2] or by using a novel ERBB3 neutralizing antibody 
(anti-B3) [24–26]. Both inhibitors were able to 
reduce AKT activation similarly to what we observed 
with lapatinib (Figure 5A). Inhibition of ERBB3 
by a specific shRNA or by the anti-ERBB3 antibody 
reduced cell survival by approximately 30%, whereas 
fucoidan had negligible effects as previously observed 
(Figure 5B, 5C). However, addition of fucoidan further 
inhibited cell survival by 76% and 70% of sh-B3 and 
anti-B3, respectively.
Interestingly, inhibitors of other classes of kinases 
relevant to melanoma such as vemurafenib, which 
target mutated BRAF, did not synergize with fucoidan 
(Supplementary Figure S4), suggesting this natural 
compound amplifies the effects of inhibitors that target 
ERBB3 signaling.
DISCUSSION
ERBB3 has recently emerged as an important player 
in melanoma. ERBB3 triggers survival cues to melanoma 
cells regardless of their oncogenic drivers [2]; ERBB3 is 
also a mechanism of resistance to BRAF inhibitors [8]; 
and promotes melanoma metastasis [9]. Hence, ERBB3 
represents an intriguing target that can potentially affect 
multiple aspects of melanoma pathogenesis. Furthermore, 
the clinical availability of several inhibitors against ERBB 
signaling would support a fast translation to melanoma.
All members of the EBBB family of receptors 
are structurally very similar but have varied functional 
activity. EGFR and ERBB4, for example, have known 
ligands and active tyrosine kinase domains. ERBB2 and 
ERBB3 structurally and functionally cooperate with each 
other as ERBB2 has an active tyrosine kinase domain, but 
no known ligand, whereas ERBB3 has a specific ligand 
(NRG1) but lacks tyrosine kinase activity. Thus, ERBB2 
remains in an open active conformation readily available 
for dimerization. In cells where PI3K is the major 
downstream signaling pathway, ERBB3 is the preferred 
dimerization partner for ERBB2 [7].
Interestingly, we have recently shown that PI3K/
AKT and NFκB are major survival pathways downstream 
ERBB3/2 in melanoma [2]; and that lapatinib effectively 
inhibits ERBB2 and ERBB3 activation [3]. In this study 
we further show that ERBB3 is as major target of the 
lapatinib and fucoidan combination. Fucoidan, extracted 
from the New Zealand seaweed U. pinnatifida, doubles 
the cell killing capacity of lapatinib and increases 
tumor inhibition over lapatinib alone while significantly 
improving the side effects associated with prolonged 
lapatinib treatment. Although fucoidan alone did not 
significantly affect tumor growth, it did show a trend at 
tumor growth inhibition. It is possible that at higher doses, 
fucoidan would be more effective alone and possibly in 
combination with lapatinb. Future studies will determine 
the best effective dose of fucoidan in vivo.
Mechanistically, addition of fucoidan to lapatinib 
results in further reduction of AKT and NFκB activation. 
Reconstitution of AKT and NFκB function restores 
almost completely cell viability and survival, indicating 
these are key factors downstream of lapatinib/fucoidan. 
Additionally, we find that while ERBB3 and ERBB2 
are affected by the treatment, EGFR was not, further 
reiterating our previous results that an ERBB3/ERBB2 
signaling cascade operates in melanoma and is mostly 
responsible of the activation of PI3K/AKT signaling 
[2]. Indeed, specific inhibition of ERBB2 recapitulated 
the effects observed with lapatinib, whereas fucoidan in 
combination with gefitinib, a specific EGFR inhibitor, did 
not exert any synergistic effects on cell viability.
That ERBB3 is a major target of the combination 
treatment is further confirmed by recapitulation of some 
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of these effects when ERBB3 is specifically knock down 
or blocked using specific shRNAs against ERBB3 or a 
selective ERBB3 neutralizing antibody. Overall these data 
indicate a combination involving the natural compound 
fucoidan and ERBB3 inhibition is a promising novel and 
safe approach in melanoma therapy.
Lapatinib has been approved for the treatment 
of breast cancer patients and a phase II clinical trial 
of lapatinib for the treatment of stage IV melanoma 
harboring ERBB4 mutations has recently been concluded 
(NCT01264081). Although analysis of the results was 
possible for a small fraction of the recruited patients, it 
did show stable disease in those patients. Nevertheless, 
it also demonstrated that lapatinib works better when in 
combination with other therapies in several cancers. For 
example, Lapatinib, in combination with capecitabine, 
has shown to extend time to disease progression 
compared to chemotherapy alone in advanced 
HER2(+) breast cancer patients that have progressed 
on trastuzumab [33]. In melanoma, it has been shown 
in preclinical models that the combination of lapatinib 
with the BRAF inhibitor PLX4720 reduces tumor burden 
and extends latency of tumor regrowth in vivo versus 
PLX4720 alone [33]. We have recently reported that 
combination of lapatinib with a γ-secretase inhibitor 
(GSI), to concurrently inhibit the ERBB and Notch 
pathways, promotes melanoma regression, whereas the 
use of either inhibitor alone can only delay tumor growth 
Figure 4: Fucoidan enhances the anti-melanoma effects of lapatinib. A. Melanoma tumor growth of WM266-4 cells. Treatments 
were started when tumors in all animals measured an average 100-120 mm3 and were given 5 days/week for three weeks. B. Statistical 
analysis (Student’s t test) at each time point comparing tumor growth of control (DMSO) vs Fuco, Lap and Lap/Fuco (left); and comparing 
Lap vs Lap/Fuco (right) C. Animal weight distribution over three weeks. The grey line refers to the relative weight at time 0. D. Alanine 
Transaminase (Liver toxicity marker) in serum (n=7 - DMSO and Fuco; n=15 - Lap and L+F). Significance between Lap and Lap/Fuco was 
calculated by Student’s t test.
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[3]. Hence, combination therapies have become standard 
of care for most cancer patients including melanoma 
patients [34].
Yet, while effective, the interaction of different 
agents in combination therapies may add further toxicities 
and may require a more careful management. Lapatinib for 
example, although generally considered well tolerated, can 
lead to gastrointestinal side effects such as diarrhea, nausea 
and vomiting that can result in weight loss, skin rash and 
fatigue, which, in the long-run can affect the quality of life 
of patients [10] [35]. Hence, means to potentiate lapatinib 
efficacy while improving its tolerability would be highly 
desirable in the clinic.
Fucoidan has been shown to synergize with standard 
anti-cancer agents and/or reduce their side effects [23]. 
For example, fucoidan enhances the efficacy of cisplatin, 
tamoxifen and paclitaxel [36] while improving their 
toxicities [37]. In our study, we observed a strong synergy 
between lapatinib and fucoidan such that addition of 
fucoidan increased the anti-tumor properties of lapatinib 
and importantly, improved the animal well-being. Mice 
did not lose any weight throughout treatment and the 
levels of ALT, a marker of liver toxicity that is increased in 
a subset of patients treated with lapatinib [38], decreased. 
Therefore, adding fucoidan to an ERBB based therapy 
may prove extremely useful particularly in those patients 
whose liver toxicity can be life threatening to the point of 
requiring suspension of the treatment.
Finally, it is worth noticing that U. pinnatifida is an 
unwanted organism that has infested and spread in several 
areas in New Zealand such that the harvest and use of 
it is encouraged and provides a relatively cheap source 
of fucoidan to be used in combination with anti ERBB 
therapies in melanoma and possibly other cancers.
Figure 5: Fucoidan cooperates with specific inhibition of ERBB3. A. Expression levels of ERBB3, phosphor-AKT in cells 
expressing a specific shERBB3 (left panel) and cells treated O/N with a specific ERBB3 neutralizing antibody (10 ug/ml) (right panel). B-
C. % survival (evaluated by trypan blue count) of cells (WM266-4) expressing shERBB3 and treated for three days with fucoidan (1 mg/
ml) (B) or treated with anti ERBB3 neutralizing antibody (10 ug/ml) and fucoidan (1 mg/ml) alone or in combination (C). P values were 




Melanoma cells used in this study were: WM266-
4, WM115 (mutated BRAF), SKMEL2 (RAS mutated), 
MeWo and FEMX (wild type). BJ fibroblasts were 
obtained from ATCC (ATCC-CRL-2522). All cells were 
maintained in DMEM (Dulbecco’s modied Eagle’s 
medium) supplemented with 10% fetal calf serum, 1% 
glutamine and 1% penicillin–streptomycin.
Crude fucoidan extraction
Sporophyll of seaweed Undaria pinnatifida 
samples were harvested from Marlborough Sounds, New 
Zealand. The samples were then processed as in [39] to 
extract crude fucoidan. Briefly, sporophylls were dried 
and treated at room temperature for 24 h with a MeOH–
CHCl3–water mixture (4:2:1) to remove lipids, protein, 
and colored pigments. The treated algal biomass was 
filtered through a Whatman’s filter paper (90 mm GF/D), 
then washed with acetone and dried overnight at room 
temperature. Treated material was mechanically stirred 
with 2% aqueous CaCl2 (100 mL) at 85°C for 5 h. The 
extract was centrifuged at 18500 g and the supernatant 
was collected. Pure ethanol was added to the extract to 
make the final ethanol concentration to reach 70% and 
the mixture was left to precipitate at 4°C overnight. The 
precipitate was centrifuged at 18500 g, washed with 
water and mechanically stirred with 60 mL ethanolic NaI 
solution (20%) for 72 h. The precipitate was removed by 
centrifugation, washed with ethanol and lyophilized to 
give crude fucoidan. An acqueous solution of fucoidan 
was used in both invitro and in vivo experiments.
Plasmids, shRNAs and chemicals
shRNAs against human ERBB3 (TRCN0000000621) 
was purchased from sigma (Saint Louis, MO, USA). 
Lapatinib was from LC Laboratories (Woburn, MA, USA). 
All compounds were dissolved in DMSO (Sigma, Saint 
Louis, MO, USA).
Luciferase assays
WM266-4 cells (5 × 104) were transfected with a 
NFκB reporter construct [40] and a CMV-driven Renilla 
reporter control at a 1:20 ratio, respectively. After 36–48 h, 
activities of Firefly and Renilla were assessed by the dual-
luciferase Assay system (Promega, Madison, WI, USA)) 
and light production was measured for 10 s in a Monolight 
2010 Luminometer (Molecular Devices, Sunnyvale, CA, 
USA).
Western blot analysis
Serum starved cells (2 × 106) were treated with 
vehicle (DMSO) or compounds at the indicated doses 
and with 10ng/ml neuregulin 1 (NRG1), and were then 
collected 24 h post-treatment. Total protein was extracted 
with urea lysis buffer (9 M urea; 75 μM Tris–HCl, pH 7.5 
and 100 μM 2-mercaptoethanol (2-ME)). 40–50 μg per 
sample were separated by 8–10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and transferred onto 
nitrocellulose membranes. Antibodies against phospho-
EGFR, phospho-ERBB2, total ERBB3 and total and 
phosphor-AKT were from Cell Signaling Technologies 
(Beverly, MA, USA). Loading was normalized with anti 
GAPDH (Santa Cruz Biotechnology).
Viability and cell death assay
Viability was evaluated by the Cell titer-Glo 
(Promega, Madison, WI, USA) as per manufacturer’s 
instructions on 3000 cells seeded in triplicate in 96-well 
plates and treated for three days with several doses of 
fucoidan and 10 μM lapatinib. Cell death was calculated 
on cells treated as above by using trypan blue.
In vivo tumor growth
Cells (2 × 106) were injected subcutaneously in the 
dorsal flanks of 8 weeks old Male SCID mice for a total 
of ten tumors and fifteen tumors per DMSO, Fucoidn and 
Lapatinib, Lap+ Fuco, respectively. Mice were supplied 
by the Athymic Animal Facility at Case Western Reserve 
University under an Administrative Panel on Laboratory 
Animal Care approved protocol. Tumors were measured 
with a caliper and tumor volumes calculated. Treatments 
were started when tumors in all animals reach an average 
size of 100-120 mm3. Mice were divided into four 
groups of treatments and received the following doses of 
compounds five consecutive days a week: 1) DMSO; 2) 
fucoidan (400mg/Kg s.c. [31]); Lapatinib (50mg/Kg I.P. 
[32]); 4) fucoidan+lapatinib.
Alanine transaminase assay
100 ul blood was collected from the tail vein one 
our after the last treatment. Blood was centrifuged at 
1000 × g and serum collected. 20 ul of serum from each 
animal was used for the analysis using the Enzychrom™ 
Alanine Transaminase Assay Kit, as per manufacturer’s 
instructions (Bioassay system, Hayward, CA).
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